Hyperfractionated, accelerated chemoradiation with concurrent mitomycin-C and cisplatin in locally advanced head and neck cancer, a phase I/II study

Radiotherapy and Oncology

Volumn 80, Issue 1, 2006, Pages 33-38

  Hehr, Thomas ^a   Classen, Johannes ^a   Welz, Stefan ^c   Ganswindt, Ute ^a   Scheithauer, Heike ^a   Koitschev, Asen ^b   Bamberg, Michael ^a   Budach, Wilfried ^c  

^a Department of Radiation Oncology ^*  (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

Acceleration; Chemoradiation; Cisplatin; Head and neck cancer; Hyperfractionation; Mitomycin C

Indexed keywords

CISPLATIN; MITOMYCIN C;

ACUTE TOXICITY; ADULT; ADVANCED CANCER; ANEMIA; ARTICLE; ASPIRATION PNEUMONIA; BLOOD TOXICITY; BLOOD TRANSFUSION; BONE NECROSIS; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CAUSE OF DEATH; CHRONIC TOXICITY; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOPENIA; DESQUAMATION; DISEASE SEVERITY; DRUG FATALITY; DRUG SAFETY; DYSPHAGIA; ERYTHEMA; FEBRILE NEUTROPENIA; FEEDING APPARATUS; FEVER; FOLLOW UP; HEAD AND NECK CANCER; HUMAN; HYPOPHARYNX CANCER; INFECTION; KIDNEY DISEASE; LARYNX CANCER; LEUKOPENIA; LYMPHEDEMA; MOUTH CANCER; MUCOSA INFLAMMATION; MUCOSAL NECROSIS; NEPHROTOXICITY; NEUTROPENIA; OROPHARYNX CANCER; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PIGMENT DISORDER; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; RADIATION INJURY; SIDE EFFECT; SKIN FIBROSIS; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; TRISMUS; WEIGHT REDUCTION; XEROSTOMIA;

ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; CARCINOMA, SQUAMOUS CELL; CISPLATIN; COMBINED MODALITY THERAPY; DOSE FRACTIONATION; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; MITOMYCIN; PROSPECTIVE STUDIES; RADIATION-SENSITIZING AGENTS; TREATMENT OUTCOME;

EID: 33747181691     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.radonc.2006.05.016     Document Type: Article

References (15)

1. Ang K.K., Harris J., Garden A.S., et al. Concomitant boost radiation plus concurrent cisplatin for advanced head and neck carcinomas: radiation therapy oncology group phase II trial 99-14. J Clin Oncol 23 (2005) 3008-3015
2. Baumann M., Bentzen S.M., and Ang K.K. Hyperfractionated radiotherapy in head and neck cancer: a second look at the clinical data. Radiother Oncol 46 (1998) 127-130
3. Beck-Bornholdt H.P., Dubben H.H., Liertz-Petersen C., and Willers H. Hyperfractionation: where do we stand?. Radiother Oncol 43 (1997) 1-21
4. Budach V., Stuschke M., Budach W., et al. Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the radiotherapy cooperative clinical trials group of the German Cancer Society 95-06 Prospective Randomized Trial. J Clin Oncol 23 (2005) 1125-1135
5. Budach W, Hehr T, Budach V, Belka C, Dietz K. A meta-analysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy and radiotherapy regimens in unresected locally advanced squamous cell carcinoma of the head and neck. BMC Cancer [submitted].
6. Dubben H.H. Local control, TCD50 and dose-time prescription habits in radiotherapy of head and neck tumours. Radiother Oncol 32 (1994) 197-200
7. Hehr T., Classen J., Schreck U., Glocker S., Bamberg M., and Budach W. Hyperfractionated accelerated radiotherapy alone and with concomittant chemotherapy of the head and neck: treated within and outside of randomized clinical trials. Int J Radiat Oncol Biol Phys 58 (2004) 1424-1430
8. Kaplan E.L., and Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 53 (1958) 457-481
9. Merlano M., Russi E.G., Numico G., et al. Paclitaxel, cisplatin, 5-fluorouracil and radiotherapy in the management of advanced squamous cell carcinoma of the head and neck: a phase II trial. Radiother Oncol 75 (2005) 193-196
10. Staar S., Rudat V., Stuetzer H., et al. Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy - results of a multicentric randomized German trial in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 50 (2001) 1161-1171 Erratum in: Int J Radiat Oncol Biol Phys 2001;51:569
11. Stuschke M., Budach V., Dinges S., et al. Accelerated hyperfractionated radiotherapy combined with simultaneous chemotherapy in locally advanced pharyngeal and oral carcinomas. Strahlenther Onkol 170 (1994) 689-699
12. Stuschke M., and Thames H.D. Hyperfractionated radiotherapy of human tumours: overview of the randomized clinical trials. Int J Radiat Oncol Biol Phys 37 (1997) 259-267
13. Sykes A.J., Slevin N.J., MacDougall R.H., Ironside J.A., and Mais K.L. Results of a phase I study to determine the maximum tolerated dose of capecitabine when given concurrently with radical radiotherapy in the treatment of squamous cell carcinoma of the head and neck. Radiother Oncol 71 (2004) 81-84
14. Trotti A., Bellm L.A., Epstein J.B., et al. Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review. Radiother Oncol 66 (2003) 253-262
15. Trotti A., and Bentzen S.M. The need for adverse effects reporting standards in oncology clinical trials. J Clin Oncol 22 (2004) 19-22